Comments

X4 Pharmaceuticals

Q: What sector and industry does X4 Pharmaceuticals (XFOR) operate in?

X4 Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

XFORNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.617500

0.00080.13%

At close: -

$0.628900

0.011.85%

After Hours: Nov 8, 7:03 PM EDT

Q3 2024 Earnings in 3 days from now on Wed Nov 13th, before the market open

X4 Pharmaceuticals (XFOR) Forecast

News Earnings X4 Pharmaceuticals (XFOR) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Overview Rating

Good

Technicals Analysis

0100

Financials Analysis

0100

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Quotes, Forecast and News Summary

X4 Pharmaceuticals Stock (NASDAQ: XFOR) stock price, news, charts, stock research, profile.

Open	$0.61
Close	$0.62
Volume / Avg.	1.01M / 1.09M
Day Range	$0.60 - $0.64
52 Wk Range	0.47 - 1.60
Market Cap	$105.97M
P/E Ratio	4.74
Dividend Yield	-
Exchange	NASDAQ
RSI	64
Short Interest	7.58%
Days to Cover	9.45

Recent News

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

Shanthi Rexaline

FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

Vandana Singh

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

May

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$0.61
Close	$0.62
Volume / Avg.	1.01M / 1.09M
Day Range	$0.60 - $0.64
52 Wk Range	0.47 - 1.60
Market Cap	$105.97M
P/E Ratio	4.74
Dividend Yield	-
Exchange	NASDAQ
RSI	64
Short Interest	7.58%
Days to Cover	9.45

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy X4 Pharmaceuticals (XFOR) stock?

You can purchase shares of X4 Pharmaceuticals (NASDAQ:XFOR) through any online brokerage.

View our list of the best stock brokerages

Who are X4 Pharmaceuticals (XFOR) competitors?

Other companies in X4 Pharmaceuticals’s space includes: Renovaro (NASDAQ:RENB), Anixa Biosciences (NASDAQ:ANIX), Citius Oncology (NASDAQ:CTOR), Adicet Bio (NASDAQ:ACET) and Cue Biopharma (NASDAQ:CUE).

What is the forecast, or price target, for X4 Pharmaceuticals (XFOR) stock?

X4 Pharmaceuticals has a consensus price target of $4.50.

What is the current price for X4 Pharmaceuticals (XFOR)?

The stock price for X4 Pharmaceuticals (NASDAQ: XFOR) is $0.6289 last updated November 8, 2024 at 7:03 PM EST.

Does X4 Pharmaceuticals (XFOR) pay a dividend?

There are no upcoming dividends for X4 Pharmaceuticals.

When is X4 Pharmaceuticals (NASDAQ:XFOR) reporting earnings?

X4 Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 13, 2024.

Is X4 Pharmaceuticals (XFOR) going to split?

There is no upcoming split for X4 Pharmaceuticals.

What sector and industry does X4 Pharmaceuticals (XFOR) operate in?

X4 Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.